ILP-2: A New Bane and Therapeutic Target for Human Cancers

Zhiliang Zhang; Zhiliang Zhang; Siqi Xiang; Siqi Xiang; Ruxia Cui; Ruxia Cui; Hang Peng; Hang Peng; Roy Mridul; Roy Mridul; Mingjun Xiang; Mingjun Xiang

doi:10.3389/fonc.2022.922596

Frontiers in Oncology (Jun 2022)

ILP-2: A New Bane and Therapeutic Target for Human Cancers

Zhiliang Zhang,
Zhiliang Zhang,
Siqi Xiang,
Siqi Xiang,
Ruxia Cui,
Ruxia Cui,
Hang Peng,
Hang Peng,
Roy Mridul,
Roy Mridul,
Mingjun Xiang,
Mingjun Xiang

Affiliations

Zhiliang Zhang: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Zhiliang Zhang: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China
Siqi Xiang: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Siqi Xiang: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China
Ruxia Cui: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Ruxia Cui: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China
Hang Peng: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Hang Peng: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China
Roy Mridul: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Roy Mridul: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China
Mingjun Xiang: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China
Mingjun Xiang: The State Ethnic Committee’s Key Laboratory of Clinical Engineering Laboratory of Xiangxi Miao Pediatric Tuina, Jishou University, Jishou, China

DOI: https://doi.org/10.3389/fonc.2022.922596
Journal volume & issue: Vol. 12

Abstract

Read online

Inhibitor of apoptosis protein-related-like protein-2 (ILP-2), also known as BIRC-8, is a member of the inhibitor of apoptosis protein (IAPs) family, which mainly encodes the negative regulator of apoptosis. It is selectively overexpressed in a variety of human tumors and can help tumor cells evade apoptosis, promote tumor cell growth, increase tumor cell aggressiveness, and appears to be involved in tumor cell resistance to chemotherapeutic drugs. Several studies have shown that downregulation of ILP-2 expression increases apoptosis, inhibits metastasis, reduces cell growth potential, and sensitizes tumor cells to chemotherapeutic drugs. In addition, ILP-2 inhibits apoptosis in a unique manner; it does not directly inhibit the activity of caspases but induces apoptosis by cooperating with other apoptosis-related proteins. Here, we review the current understanding of the various roles of ILP-2 in the apoptotic cascade and explore the use of interfering ILP-2, and the combination of related anti-tumor agents, as a novel strategy for cancer therapy.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords